scholarly journals Association between lung function and exacerbation frequency in patients with COPD

2010 ◽  
pp. 435 ◽  
Author(s):  
Hoogendoorn
Keyword(s):  
Lung Function ◽  
Exacerbation Frequency

scholarly journals Single inhaler triple therapy in COPD – all that glitters is not gold

2021 ◽  
Vol 91 (2) ◽  
Author(s):  
Kartik Deshmukh ◽  
Arjun Khanna
Keyword(s):  
Lung Function ◽  
Triple Therapy ◽  
Inhaled Corticosteroid ◽  
Muscarinic Antagonist ◽  
Exacerbation Frequency ◽  
Long Acting ◽  
Beta2 Agonist

Dear Editor, The recent studies on combination triple therapy of inhaled corticosteroid, long acting beta2 agonist and long-acting muscarinic antagonist (ICS-LABA-LAMA) in COPD have consistently demonstrated an improvement in exacerbation frequency and/or improvement of lung function...

scholarly journals Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach

2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Kathrin Kahnert ◽  
Peter Alter ◽  
Tobias Welte ◽  
Rudolf M. Huber ◽  
Jürgen Behr ◽  
...  
Keyword(s):  
Uric Acid ◽  
Lung Function ◽  
Physical Capacity ◽  
Dimensional Approach ◽  
Exacerbation Frequency

scholarly journals FUT2genotype influences lung function, exacerbation frequency and airway microbiota in non-CF bronchiectasis

Thorax ◽  
2016 ◽  
Vol 72 (4) ◽  
pp. 304-310 ◽  
Author(s):  
Steven L Taylor ◽  
Richard J Woodman ◽  
Alice CH Chen ◽  
Lucy D Burr ◽  
David L Gordon ◽  
...  
Keyword(s):  
Lung Function ◽  
Exacerbation Frequency

scholarly journals Defective monocyte-derived macrophage phagocytosis is associated with exacerbation frequency in COPD

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
R. Singh ◽  
◽  
K. B. R. Belchamber ◽  
P. S. Fenwick ◽  
K. Chana ◽  
...  
Keyword(s):  
Lung Function ◽  
Inhaled Corticosteroids ◽  
Stable State ◽  
Smoking History ◽  
Lower Airway ◽  
Lung Function Decline ◽  
Bacterial Colonisation ◽  
Exacerbation Frequency ◽  
Macrophage Phagocytosis ◽  
Copd Patients

Abstract Background Lower airway bacterial colonisation (LABC) in COPD patients is associated with increased exacerbation frequency and faster lung function decline. Defective macrophage phagocytosis in COPD drives inflammation, but how defective macrophage function contributes to exacerbations is not clear. This study investigated the association between macrophage phagocytosis and exacerbation frequency, LABC and clinical parameters. Methods Monocyte-derived macrophages (MDM) were generated from 92 stable COPD patients, and at the onset of exacerbation in 39 patients. Macrophages were exposed to fluorescently labelled Haemophilus influenzae or Streptococcus pneumoniae for 4 h, then phagocytosis measured by fluorimetry and cytokine release by ELISA. Sputum bacterial colonisation was measured by PCR. Results Phagocytosis of H. influenzae was negatively correlated with exacerbation frequency (r = 0.440, p < 0.01), and was significantly reduced in frequent vs. infrequent exacerbators (1.9 × 103 RFU vs. 2.5 × 103 RFU, p < 0.01). There was no correlation for S. pneumoniae. There was no association between phagocytosis of either bacteria with age, lung function, smoking history or treatment with inhaled corticosteroids, or long-acting bronchodilators. Phagocytosis was not altered during an exacerbation, or in the 2 weeks post-exacerbation. In response to phagocytosis, MDM from exacerbating patients showed increased release of CXCL-8 (p < 0.001) and TNFα (p < 0.01) compared to stable state. Conclusion Impaired COPD macrophage phagocytosis of H. influenzae, but not S. pneumoniae is associated with exacerbation frequency, resulting in pro-inflammatory macrophages that may contribute to disease progression. Targeting these frequent exacerbators with drugs that improve macrophage phagocytosis may prove beneficial.

scholarly journals The use of roflumilast in COPD: a review

2015 ◽  
Vol 79 (3-4) ◽  
Author(s):  
Andrea Zanini ◽  
Francesca Cherubino ◽  
Patrizia Pignatti
Keyword(s):  
Lung Function ◽  
Treatment Options ◽  
Forced Expiratory Volume ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Phosphodiesterase 4 ◽  
Positive Effects ◽  
Exacerbation Frequency ◽  
Copd Patients ◽  
Significant Additive Effect

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Chronic inflammation and exacerbations play a central role in the progression of the disease. Currently, treatment options for COPD have been shown to improve the progressive decline in lung-function and/or decrease mortality rates. Roflumilast, a phosphodiesterase- 4 inhibitor, is an anti-inflammatory drug which has been licensed as an add-on therapy for COPD patients with forced expiratory volume in the first second &lt;50% and frequent exacerbations. Clinical trials have demonstrated that roflumilast improves lung function and reduces exacerbation frequency. Roflumilast has a mechanism of action which allows it to obtain a significant additive effect to current therapeutic options for COPD patients. It is generally well tolerated, although the most common adverse effects include diarrhea, nausea, weight loss, and headache. This review article provides an overview of the positive effects of roflumilast on lung function, exacerbation frequency and glucose metabolism, and its interaction with concomitant inhaled treatments.

Sign in / Sign up

Export Citation Format

Share Document